Hodgkin's lymphoma: better outcomes with fewer drugs?
Mené sur 1 502 patients atteints d'un lymphome hodgkinien de stade précoce et de pronostic favorable, cet essai randomisé multicentrique évalue l'intérêt d'omettre, dans un protocole ABVD (doxorubicine, bléomycine, vinblastine et dacarbazine), la bléomycine et/ou la dacarbazine (durée de suivi : 5 ans)
In The Lancet, Karolin Behringer and colleagues from the German Hodgkin Study Group report results from their four-group trial (HD13) that randomly assigned 1502 patients with early-stage favourable-risk Hodgkin's lymphoma to two cycles of either standard ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy or one of three experimental treatments omitting either dacarbazine (ABV), or bleomycin (AVD), or both, all followed by 30 Gy involved-field radiotherapy (IFRT). They aimed to investigate whether omission of one or both of dacarbazine and bleomycin reduced the efficacy of this regimen in treatment of Hodgkin's lymphoma.
The Lancet , commentaire, 2014